Evidence map›Paper›PMID 33172842›Full record

ArticleImmunoHorizons2020

Dapeng Li, Todd Bradley, Derek W Cain, Isabela Pedroza-Pacheco, Maria Aggelakopoulou, Robert Parks, Maggie Barr, Shi-Mao Xia, Richard Scearce, Cindy Bowman and 10 more

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Dapeng LiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710; dapeng.li@duke.edu barton.haynes@duke.edu.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Isabela Pedroza-PachecoNuffield Department of Clinical Medicine, University of Oxford, OX3 7FZ Oxford, United Kingdom.
Maria AggelakopoulouNuffield Department of Clinical Medicine, University of Oxford, OX3 7FZ Oxford, United Kingdom.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Shi-Mao XiaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Richard ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Cindy BowmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0002-6903-2831
Grace StevensDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0002-8696-9319
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Bhavna HoraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Yue ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Kristina RiebeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0003-4936-4756
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Gregory SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0001-7399-7954
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, OX3 7FZ Oxford, United Kingdom.ORCID 0000-0002-3877-9780
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710; dapeng.li@duke.edu barton.haynes@duke.edu.
Duke University · USNuffield Orthopaedic Centre · GB

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MOODY, MICHAEL ANTHONY · 2012 to 2018
$204.7M
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Natural killer cell regulation of the germinal center HIV neutralizing antibody responseR01AI147778 · NIAID · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI BRADLEY, TODD CHRISTOPHER · 2020 to 2024
$3.6M
Medical Research Council MR/K012037/1NIAID NIH HHS R01 AI147778NIAID NIH HHS UC6 AI058607NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371
6 · The paper itself

Abstract

Rab11 recycling endosomes are involved in immunological synaptic functions, but the roles of Rab11 family-interacting protein 5 (Rab11Fip5), one of the Rab11 effectors, in the immune system remain obscure. Our previous study demonstrated that

Indexed as

TranscriptomeAdaptor Proteins, Signal TransducingAnimalsAntibodies, NeutralizingCD8-Positive T-LymphocytesCytokinesFemaleHIV-1HIV InfectionsHumansKiller Cells, NaturalMaleMiceMice, Inbred C57BLAdaptor Proteins, Signal TransducingAntibodies, NeutralizingCytokinesRAB11FIP5 protein, human

Identifiers

PMID33172842
PMCPMC8050958
OpenAlexW3106530411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.